Immunoprecise Historical Balance Sheet
IPA Stock | USD 1.22 0.03 2.40% |
Trend analysis of Immunoprecise Antibodies balance sheet accounts such as Total Current Liabilities of 7.1 M or Total Stockholder Equity of 69.8 M provides information on Immunoprecise Antibodies' total assets, liabilities, and equity, which is the actual value of Immunoprecise Antibodies to its prevalent stockholders. By breaking down trends over time using Immunoprecise Antibodies balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Immunoprecise Antibodies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunoprecise Antibodies is a good buy for the upcoming year.
Immunoprecise Antibodies Inventory |
|
Immunoprecise |
About Immunoprecise Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Immunoprecise Antibodies at a specified time, usually calculated after every quarter, six months, or one year. Immunoprecise Antibodies Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunoprecise Antibodies and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunoprecise currently owns. An asset can also be divided into two categories, current and non-current.
Immunoprecise Antibodies Balance Sheet Chart
Immunoprecise Antibodies Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Immunoprecise Antibodies uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Immunoprecise Antibodies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 599.4 K, whereas Net Debt is forecasted to decline to (957.3 K). Add Fundamental
Total Assets
Total assets refers to the total amount of Immunoprecise Antibodies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunoprecise Antibodies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Immunoprecise Antibodies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunoprecise Antibodies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most accounts from Immunoprecise Antibodies' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 599.4 K, whereas Net Debt is forecasted to decline to (957.3 K).
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 1.3M | 441K | 507.2K | 599.4K | Total Assets | 93.5M | 77.8M | 89.5M | 94.0M |
Immunoprecise Antibodies balance sheet Correlations
Click cells to compare fundamentals
Immunoprecise Antibodies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunoprecise Antibodies balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Liab | 1.8M | 964K | 1.3M | 441K | 507.2K | 599.4K | |
Total Current Liabilities | 7.9M | 6.1M | 9.3M | 5.9M | 6.8M | 7.1M | |
Total Stockholder Equity | 15.1M | 56.9M | 75.3M | 57.8M | 66.5M | 69.8M | |
Property Plant And Equipment Net | 3.2M | 4.1M | 3.7M | 10.7M | 12.3M | 12.9M | |
Net Debt | 1.9M | (38.3M) | (27.4M) | (1.0M) | (911.7K) | (957.3K) | |
Retained Earnings | (22.5M) | (29.8M) | (46.5M) | (73.1M) | (65.8M) | (62.5M) | |
Accounts Payable | 1.8M | 3.0M | 4.8M | 3.4M | 3.9M | 4.1M | |
Cash | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Non Current Assets Total | 19.6M | 18.1M | 56.0M | 61.0M | 70.2M | 73.7M | |
Cash And Short Term Investments | 2.6M | 41.8M | 30.0M | 8.3M | 9.5M | 10.0M | |
Net Receivables | 3.7M | 4.1M | 3.4M | 4.4M | 5.1M | 5.3M | |
Common Stock Shares Outstanding | 13.6M | 16.5M | 19.7M | 24.9M | 28.6M | 30.1M | |
Liabilities And Stockholders Equity | 27.3M | 67.0M | 93.5M | 77.8M | 89.5M | 94.0M | |
Other Current Assets | 614.0K | 2.3M | 2.8M | 2.6M | 3.0M | 3.1M | |
Other Stockholder Equity | 3.5M | 6.6M | 7.3M | 10.8M | 9.7M | 10.0M | |
Total Liab | 12.2M | 10.0M | 18.2M | 20.0M | 23.0M | 24.2M | |
Total Current Assets | 7.7M | 48.9M | 37.5M | 16.8M | 19.3M | 20.3M | |
Non Current Liabilities Total | 4.2M | 4.0M | 8.9M | 14.1M | 16.2M | 17.0M | |
Non Currrent Assets Other | 85.1K | 79K | 82K | 86K | 77.4K | 73.5K | |
Short Long Term Debt Total | 4.5M | 3.5M | 2.5M | 7.3M | 8.4M | 8.8M | |
Property Plant And Equipment Gross | 3.1M | 4.1M | 9.4M | 17.1M | 19.6M | 20.6M | |
Accumulated Other Comprehensive Income | (300.2K) | (687K) | (2.5M) | 2.6M | 2.4M | 2.5M | |
Short Term Debt | 2.9M | 986K | 2.2M | 1.1M | 1.3M | 1.1M | |
Inventory | 818.6K | 1.2M | 1.6M | 2.1M | 2.4M | 2.5M | |
Current Deferred Revenue | 1.5M | 1.1M | 1.0M | 977K | 1.1M | 567.8K | |
Net Tangible Assets | (1.0M) | 43.1M | 23.2M | 7.7M | 8.9M | 12.5M | |
Net Invested Capital | 17.7M | 58.5M | 76.6M | 57.8M | 66.5M | 39.4M | |
Net Working Capital | (230.3K) | 42.8M | 28.2M | 10.9M | 12.5M | 13.7M | |
Common Stock | 34.1M | 80.1M | 114.6M | 117.5M | 135.1M | 141.8M | |
Property Plant Equipment | 3.1M | 4.0M | 3.3M | 10.4M | 12.0M | 12.5M | |
Other Liab | 2.6M | 1.5M | 8.6M | 7.9M | 9.1M | 5.1M | |
Other Assets | 287.6K | 163K | 476K | 437K | 393.3K | 373.6K | |
Good Will | 7.9M | 7.8M | 19.7M | 19.2M | 22.0M | 12.4M | |
Capital Lease Obligations | 1.9M | 1.9M | 1.2M | 7.3M | 8.4M | 8.8M | |
Long Term Investments | 118.9K | 111K | 142K | 115K | 132.3K | 122.4K | |
Intangible Assets | 8.3M | 6.1M | 32.4M | 30.9M | 35.6M | 37.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.939 | Quarterly Revenue Growth 0.203 | Return On Assets (0.11) | Return On Equity (0.26) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.